Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Imagem de Miniatura
Arquivos
art_ARAI_Serum_levels_of_VEGF_and_MCSF_in_HER2HER2_2018.PDF (711.06 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Autores
Citação
BIOMARKER RESEARCH, v.6, article ID 20, 6p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Metronomic therapy has been gaining importance in the neoadjuvant setting of breast cancer treatment. Its clinical benefits may involve antiangiogenic machinery. Cancer cells induce angiogenesis to support tumor growth by secreting factors, such as vascular endothelial growth factor (VEGF). In breast cancer, Trastuzumab (TZM) based treatment is of key importance and is believed to reduce diameter and volume of blood vessels as well as vascular permeability. Here in we investigated serum levels of angiogenic factors VEGF and MCSF in patients receiving metronomic neoadjuvant therapy with or without TZM. We observed in HER2+ cohort stable levels of MCSF through treatment, whereas VEGF trend was of decreasing levels. In HER2- cohort we observed increasing levels of MCSF and VEGF trend. Overall, HER2+ patients had better pathological response to treatment. These findings suggest that angiogenic pathway may be involved in TZM anti-tumoral effect in the neoadjuvant setting.
Palavras-chave
Metronomic chemotherapy, Angiogenesis, Biomarker, Neoadjuvant, Breast cancer
URI
https://observatorio.fm.usp.br/handle/OPI/29431
Referências
  1. Bocci G, 2002, CANCER RES, V62, P6938
  2. Bottini A, 2006, J CLIN ONCOL, V24, P3623, DOI 10.1200/JCO.2005.04.5773
  3. Browder T, 2000, CANCER RES, V60, P1878
  4. Cameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8
  5. DANFORTH DN, 1990, AM SURGEON, V56, P6
  6. Dellapasqua S, 2011, BREAST, V20, P319, DOI 10.1016/j.breast.2011.02.014
  7. Dvorak HF, 1999, AM J PATHOL, V149, P1029
  8. Emmenegger U, 2010, RECENT RESULTS CANC, V180, P165, DOI 10.1007/978-3-540-78281-0_10
  9. Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
  10. Eubank TD, 2003, J IMMUNOL, V171, P2637, DOI 10.4049/jimmunol.171.5.2637
  11. Gianni L, 2013, J CLIN ONCOL, V31, P1719, DOI 10.1200/JCO.2012.44.7912
  12. Heer K, 2001, CLIN CANCER RES, V7, P3491
  13. Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b
  14. Kalsi T, 2014, BRIT J CANCER, V111, P2224, DOI 10.1038/bjc.2014.496
  15. Kang H, 2013, KOREAN J ANESTHESIOL, V64, P402, DOI 10.4097/kjae.2013.64.5.402
  16. Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369
  17. Lange T, 2011, CANCER LETT, V308, P54, DOI 10.1016/j.canlet.2011.04.013
  18. Lawicki S, 2016, ONCOTARGETS THER, V9, P911, DOI 10.2147/OTT.S99959
  19. Loven D, 2008, ACTA ONCOL, V47, P104, DOI 10.1080/02841860701472470
  20. Mackey JR, 2015, J CLIN ONCOL, V33, P141, DOI 10.1200/JCO.2014.57.1513
  21. Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
  22. Munoz R, 2005, BREAST, V14, P466, DOI 10.1016/j.breast.2005.08.026
  23. Munzone E, 2017, CANCER LETT, V400, P259, DOI 10.1016/j.canlet.2016.12.041
  24. Osada T, 2008, CANCER IMMUNOL IMMUN, V57, P1115, DOI 10.1007/s00262-007-0441-x
  25. Pasquier E, 2007, CURR CANCER DRUG TAR, V7, P566, DOI 10.2174/156800907781662266
  26. Pasquier E, 2010, NAT REV CLIN ONCOL, V7, P455, DOI 10.1038/nrclinonc.2010.82
  27. Petry V, 2015, BRAZ J MED BIOL RES, V48, P479, DOI 10.1590/1414-431X20144354
  28. Rice A, 2002, J CLIN PATHOL, V55, P569, DOI 10.1136/jcp.55.8.569
  29. Schneider BP, 2008, J CLIN ONCOL, V26, P4672, DOI 10.1200/JCO.2008.16.1612
  30. SCHWARTZ GF, 1994, CANCER, V73, P362, DOI 10.1002/1097-0142(19940115)73:2<362::AID-CNCR2820730221>3.0.CO;2-L
  31. Slamon DJ, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-S1-03
  32. Sledge GW, 2015, J CLIN ONCOL, V33, P133, DOI 10.1200/JCO.2014.58.1298
  33. Sweeney CJ, 2001, CANCER RES, V61, P3369
  34. Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399
  35. Tuck MK, 2009, J PROTEOME RES, V8, P113, DOI 10.1021/pr800545q
  36. Voron T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00070
  37. Wildiers H, 2018, LANCET ONCOL, V19, P323, DOI 10.1016/S1470-2045(18)30083-4
  38. Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
  39. Wong NS, 2010, J CLIN ONCOL, V28, P723, DOI 10.1200/JCO.2009.24.0143
  40. Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.E02-02-0084

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03